Michael A. Metzger, CEO of Syndax Pharmaceuticals ($SNDX), sold shares on the open market four times over the past year, totaling $3.2 million. His most recent sale occurred on February 9, 2026. These sales rank 2625th among 11,678 individual insiders in our database, where the average is $8.6 million across about 6.4 transactions per insider. Metzger made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 24, 2026 | Pyxis Oncology, Inc. | $PYXS | Metzger Michael A | Not found | A | Stock Option (Right to Buy) | 45867 | $0.00 | 45,867.0000 | 62,557,386 | 9999.99% | 0.07% |
| Feb. 9, 2026 | Syndax Pharmaceuticals Inc | $SNDX | Metzger Michael A | Chief Executive Officer | S | Common Stock | 17159 | $21.03 | 491,690.0000 | 86,914,838 | 3.37% | 0.02% |
| Feb. 4, 2026 | Syndax Pharmaceuticals Inc | $SNDX | Metzger Michael A | Chief Executive Officer | A | Common Stock | 73000 | $0.00 | 371,661.0000 | 86,914,838 | 24.44% | 0.08% |
| Feb. 4, 2026 | Syndax Pharmaceuticals Inc | $SNDX | Metzger Michael A | Chief Executive Officer | A | Stock Options (Right to buy) | 440000 | $20.43 | 440,000.0000 | 86,914,838 | 9999.99% | 0.51% |
| Feb. 6, 2026 | Syndax Pharmaceuticals Inc | $SNDX | Metzger Michael A | Chief Executive Officer | S | Common Stock | 7412 | $20.62 | 508,849.0000 | 86,914,838 | 1.44% | 0.01% |
| Feb. 4, 2026 | Syndax Pharmaceuticals Inc | $SNDX | Metzger Michael A | Chief Executive Officer | A | Common Stock | 144600 | $0.00 | 516,261.0000 | 86,914,838 | 38.91% | 0.17% |
| Sept. 8, 2025 | Syndax Pharmaceuticals Inc | $SNDX | Metzger Michael A | Chief Executive Officer | S | Common Stock | 157307 | $16.41 | 298,661.0000 | 86,024,394 | 34.50% | 0.18% |
| Sept. 8, 2025 | Syndax Pharmaceuticals Inc | $SNDX | Metzger Michael A | Chief Executive Officer | M | Common Stock | 157307 | $10.90 | 455,968.0000 | 86,024,394 | 52.67% | 0.18% |
| Sept. 8, 2025 | Syndax Pharmaceuticals Inc | $SNDX | Metzger Michael A | Chief Executive Officer | M | Stock options (Right to buy) | 157307 | $0.00 | 0.0000 | 86,024,394 | 0.00% | 0.18% |
| July 16, 2025 | Syndax Pharmaceuticals Inc | $SNDX | Metzger Michael A | Chief Executive Officer | S | Common Stock | 7534 | $9.29 | 298,661.0000 | 86,024,394 | 2.46% | 0.01% |
| March 31, 2025 | Pyxis Oncology, Inc. | $PYXS | Metzger Michael A | Not found | A | Stock Option (Right to Buy) | 36979 | $0.98 | 36,979.0000 | 58,445,765 | 9999.99% | 0.06% |
| March 14, 2025 | Syndax Pharmaceuticals Inc | $SNDX | Metzger Michael A | Chief Executive Officer | M | Common Stock | 6074 | $7.20 | 306,195.0000 | 86,024,394 | 2.02% | 0.01% |
| March 14, 2025 | Syndax Pharmaceuticals Inc | $SNDX | Metzger Michael A | Chief Executive Officer | M | Stock options (Right to buy) | 6074 | $0.00 | 0.0000 | 86,024,394 | 0.00% | 0.01% |
| March 4, 2025 | Syndax Pharmaceuticals Inc | $SNDX | Metzger Michael A | Chief Executive Officer | M | Stock options (Right to buy) | 7814 | $0.00 | 0.0000 | 86,024,394 | 0.00% | 0.01% |
| March 4, 2025 | Syndax Pharmaceuticals Inc | $SNDX | Metzger Michael A | Chief Executive Officer | M | Common Stock | 7814 | $7.20 | 307,935.0000 | 86,024,394 | 2.60% | 0.01% |
| March 4, 2025 | Syndax Pharmaceuticals Inc | $SNDX | Metzger Michael A | Chief Executive Officer | S | Common Stock | 7814 | $15.05 | 300,121.0000 | 86,024,394 | 2.54% | 0.01% |
| Feb. 10, 2025 | Syndax Pharmaceuticals Inc | $SNDX | Metzger Michael A | Chief Executive Officer | S | Common Stock | 13288 | $15.50 | 300,121.0000 | 0 | 4.24% | 0.00% |
| Feb. 5, 2025 | Syndax Pharmaceuticals Inc | $SNDX | Metzger Michael A | Chief Executive Officer | A | Common Stock | 60500 | $0.00 | 224,409.0000 | 0 | 36.91% | 0.00% |
| Feb. 5, 2025 | Syndax Pharmaceuticals Inc | $SNDX | Metzger Michael A | Chief Executive Officer | A | Stock Options (Right to buy) | 364000 | $14.65 | 364,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 5, 2025 | Syndax Pharmaceuticals Inc | $SNDX | Metzger Michael A | Chief Executive Officer | A | Common Stock | 89000 | $0.00 | 313,409.0000 | 0 | 39.66% | 0.00% |
| June 10, 2024 | Pyxis Oncology, Inc. | $PYXS | Metzger Michael A | Not found | A | Stock Option (Right to Buy) | 70683 | $0.00 | 70,683.0000 | 39,904,603 | 9999.99% | 0.18% |
| Feb. 7, 2024 | Syndax Pharmaceuticals Inc | $SNDX | Metzger Michael A | Chief Executive Officer | A | Common Stock | 107250 | $0.00 | 124,909.0000 | 0 | 607.34% | 0.00% |
| Feb. 7, 2024 | Syndax Pharmaceuticals Inc | $SNDX | Metzger Michael A | Chief Executive Officer | A | Stock Options (Right to buy) | 214500 | $22.28 | 214,500.0000 | 0 | 9999.99% | 0.00% |
| Feb. 7, 2024 | Syndax Pharmaceuticals Inc | $SNDX | Metzger Michael A | Chief Executive Officer | A | Common Stock | 39000 | $0.00 | 163,909.0000 | 0 | 31.22% | 0.00% |
| Feb. 6, 2023 | Syndax Pharmaceuticals Inc | $SNDX | Metzger Michael A | Chief Executive Officer | M | Common Stock | 5959 | $6.38 | 23,618.0000 | 0 | 33.74% | 0.00% |
| Feb. 6, 2023 | Syndax Pharmaceuticals Inc | $SNDX | Metzger Michael A | Chief Executive Officer | M | Stock Options (Right to buy) | 5959 | $27.64 | 0.0000 | 0 | 100.00% | 0.00% |
| Feb. 6, 2023 | Syndax Pharmaceuticals Inc | $SNDX | Metzger Michael A | Chief Executive Officer | S | Common Stock | 5959 | $27.64 | 17,659.0000 | 0 | 25.23% | 0.00% |
| Feb. 2, 2023 | Syndax Pharmaceuticals Inc | $SNDX | Metzger Michael A | Chief Executive Officer | A | Stock Options (Right to buy) | 410000 | $28.55 | 410,000.0000 | 0 | 9999.99% | 0.00% |